Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat.

Troglitazone is a thiazolidinedione insulin sensitizer drug for the treatment of type 2 non-insulin-dependent diabetes mellitus (NIDDM). Based on an increasing number of reports on troglitazone-associated liver toxicity, the cholestatic potential of troglitazone has been investigated. Rapid and dose-dependent increases in the plasma bile acid concentrations were observed in rats after a single intravenous administration of troglitazone. A radiolabeled taurocholic acid tracer accumulated in liver tissue, indicating an interference with the hepatobiliary export of bile acids. In isolated canalicular rat liver plasma membrane preparations, troglitazone competitively inhibited the ATP-dependent taurocholate transport (apparent K(i) value, 1.3 microM), mediated by the canalicular bile salt export pump (Bsep). Troglitazone sulfate, the main troglitazone metabolite eliminated into bile, also showed competitive Bsep inhibition with an apparent K(i) value of 0.23 microM. A comparable inhibition was observed for both compounds in canalicular plasma membrane vesicles prepared from Mrp2-deficient (TR(-)) rats, suggesting a direct (cis-) inhibition of Bsep by troglitazone and troglitazone sulfate. A high accumulation potential was observed for troglitazone sulfate in rat liver tissue, indicating that the hepatobiliary export of this conjugated metabolite might represent a rate-limiting step in the overall elimination process of troglitazone. This accumulation in combination with the high Bsep inhibition potential suggested that mainly troglitazone sulfate was responsible for the interaction with the hepatobiliary export of bile acids at the level of the canalicular Bsep in rats. Such an interaction might lead to a troglitazone-induced intrahepatic cholestasis in humans as well, contributing to the formation of a troglitazone-induced liver toxicity.

[1]  K. Saigenji,et al.  An Autopsy Case of Troglitazone-Induced Fulminant Hepatitis , 1998, Diabetes Care.

[2]  T. Kinoshita,et al.  Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs. , 1997, Arzneimittel-Forschung.

[3]  W. O'Neill.  ...and other diseases , 1994 .

[4]  P. Jansen,et al.  Selective hepatobiliary transport of nordeoxycholate side chain conjugates in mutant rats with a canalicular transport defect , 1989, Hepatology.

[5]  C. Spurr,et al.  Two Cases of Severe Clinical and Histologic Hepatotoxicity Associated with Troglitazone , 1998, Annals of Internal Medicine.

[6]  P. Meier,et al.  ATP-dependent bile-salt transport in canalicular rat liver plasma-membrane vesicles. , 1992, The Biochemical journal.

[7]  P. Meier,et al.  Extrahepatic obstructive cholestasis reverses the bile salt secretory polarity of rat hepatocytes. , 1989, The Journal of clinical investigation.

[8]  S. Herrine,et al.  Severe hepatotoxicity associated with troglitazone. , 1999, Annals of internal medicine.

[9]  L. Ranek,et al.  Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency , 1998, European Journal of Clinical Pharmacology.

[10]  B. Neuschwander‐Tetri,et al.  Troglitazone-Induced Hepatic Failure Leading to Liver Transplantation: A Case Report , 1998, Annals of Internal Medicine.

[11]  J. Boyer,et al.  Properties of the canalicular bile acid transport system in rat liver. , 1987, The Biochemical journal.

[12]  P. Bosma,et al.  Congenital Jaundice in Rats with a Mutation in a Multidrug Resistance-Associated Protein Gene , 1996, Science.

[13]  Y. Bacq,et al.  Intrahepatic cholestasis of pregnancy: A French prospective study , 1997, Hepatology.

[14]  F. Kuipers,et al.  Isolation and characterization of canalicular and basolateral plasma membrane fractions from human liver. , 1991, Biochimica et biophysica acta.

[15]  P. K. Smith,et al.  Measurement of protein using bicinchoninic acid. , 1985, Analytical biochemistry.

[16]  E. Keeffe,et al.  Validation of a recording spectrophotometric method for measurement of membrane-associated Mg- and NaK-ATPase activity. , 1979, The Journal of laboratory and clinical medicine.

[17]  M. Roden,et al.  Acute troglitazone action in isolated perfused rat liver , 1999, British journal of pharmacology.

[18]  T. Berghaus,et al.  Thrombotic thrombocytopenic purpura after Ecstasy-induced acute liver failure. , 1999, Annals of internal medicine.

[19]  J. Drewe,et al.  Sister of P-glycoprotein expression in different tissues. , 1999, Biochemical pharmacology.

[20]  J. Boyer,et al.  Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver , 1984, The Journal of cell biology.

[21]  D. Keppler,et al.  ATP-dependent export pumps and their inhibition by cyclosporins. , 1994, Advances in enzyme regulation.

[22]  G. Alroy,et al.  Fatal Toxic Intrahepatic Cholestasis Secondary to Glibenclamide , 1996, Diabetes Care.

[23]  J. Boyer,et al.  Molecular pathogenesis of cholestasis. , 2012, The New England journal of medicine.

[24]  M. Müller,et al.  The secretory function of the liver: new aspects of hepatobiliary transport. , 1998, Journal of hepatology.

[25]  M. Roberfroid,et al.  Comparative hepatotoxicity of cholic acid, deoxycholic acid and lithocholic acid in the rat: in vivo and in vitro studies. , 1992, Toxicology letters.

[26]  J. Boyer,et al.  Biochemical Separation of Na+, K+‐ATPase from a “Purified” Light Density, “Canalicular”‐Enriched Plasma Membrane Fraction from Rat Liver , 2007, Hepatology.

[27]  V. Desmet.  Histopathology of cholestasis. , 1995, Verhandlungen der Deutschen Gesellschaft fur Pathologie.

[28]  L. Ranek,et al.  Pharmacokinetics of troglitazone, a PPAR-gamma agonist, in patients with hepatic insufficiency. , 1998, European journal of clinical pharmacology.

[29]  J. A. Goldbarg,et al.  The colorimetric determination of leucine aminopeptidase in urine and serum of normal subjects and patients with cancer and other diseases , 1958, Cancer.

[30]  R. Vonk,et al.  ATP-DEPENDENT TAUROCHOLATE TRANSPORT IN CANALICULAR AND BASOLATERAL PLASMA-MEMBRANE VESICLES ISOLATED FROM HUMAN LIVER , 1993 .

[31]  E. Randinitis,et al.  Clinical Pharmacokinetics of Troglitazone , 1999, Clinical pharmacokinetics.

[32]  A. Hofmann,et al.  Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. , 1999, Gastroenterology.

[33]  C. Chen.  Troglitazone: an antidiabetic agent. , 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[34]  F. Suchy,et al.  Hepatobiliary Transport: Molecular Mechanisms of Development and Cholestasis , 1998, Pediatric Research.

[35]  Y. Awasthi,et al.  Mechanisms for xenobiotic transport in biological membranes. , 1999, Toxicology letters.

[36]  P. Meier,et al.  Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver. , 2000, Gastroenterology.

[37]  T. Ishikawa,et al.  Inhibition by cyclosporin A of adenosine triphosphate-dependent transport from the hepatocyte into bile. , 1993, Gastroenterology.

[38]  G. Gores,et al.  Induction of the mitochondrial permeability transition as a mechanism of liver injury during cholestasis: a potential role for mitochondrial proteases. , 1998, Biochimica et biophysica acta.

[39]  N. Kawada,et al.  [Drug-induced cholestasis]. , 1995, Ryoikibetsu shokogun shirizu.

[40]  E. Keeffe,et al.  Studies of relationship among bile flow, liver plasma membrane NaK-ATPase, and membrane microviscosity in the rat. , 1979, The Journal of clinical investigation.